All the Therapeutic System Drugs
Human C1-esterase Inhibitor 500 IU/vial. VIAL: 1 (+ solv). Adult, child: Slow I.V.
inject./infus: 20 units/kg.
Tmt. acute episodes heredit. angioedem.
type I, II (HAE).
Bradykinin β-2 Receptor antagonist. Icatibant (as acetate) 30 mg / 3 ml. PREFILL. SYR. (sol. for inject.): 1 ×3 ml.
1 x 30 mg S.C. inj. in abd. area given
slowly. 1 inj. should suffic. In case of
recur. in adults can admin. 2nd inject aft. 6 hrs. or a 3rd
inj. aft. another 6 hrs. max. 3 inj. in 24 hrs. See lit.
Sympt. tmt. acute attacks hereditary
angioedema (HAE) in adults, adolesc. & child. aged 2 yrs and old. with
C1-esterase-inhib. defic.
C/I: Hypersens.
Bradykinin B2 Receptor Antagonist. Icatibant (as acetate) 30 mg / 3 ml. SYR. (Sol. for S.C. inj.).: 1. One S.C. inj. of Icatibant (3 ml/30 mg), as soon as signs of attack are detected (e.g. swelling of the skin, especially in the area of the face and neck, or increas. abdom. pain).
If the condition is not improved in 6 hrs., another 3 ml dose may be admin.
If there is still no improv., a 3rd dose may be admin. after another 6 hrs.
No more than 3 doses in 24 hrs. and no more than 8 inj. of icatibant in one month. Child.& adolesc. 2-17 yrs. of age: 1 ml up to a max. of 3 ml, inject. S.C. accord. to bdy. wt. (one syr. contains 3 ml), as soon as signs of angioedema attack develop (e.g. incr.swell. of the skin, especially in the area of the face and neck, or increas. abd. pain). See lit.
Symptomat. tmt .of acute attacks of hereditary angioedima (HAE) in adult., adolesc. & child. aged 2 yrs. and older, with C1-esterase-inhib. defic.
C/I: Hypersens.
Drugs used in Hereditary Angioedema, Kallikrein Inhibitor Berotralstat. Berotralstat 110 mg, 150 mg. Caps. 110/150 mg X 28
150 mg orally once/d. Mod. or sev. hepatic imp. (Child-Pugh B or C): 110 mg /d. Pts. with chronic admin. of P-gp or BCRP inhibit. (e.g., cyclosporine): 110 mg /d
Prevent. of attacks of hereditary angioedema (HAE) in adlts. and ped. pts. 12 years and older. Limit. of use: safety and effectiv. for tmt. of ac. HAE attacks have not been establish., not be used for acute HAE attacks. Addit. doses or doses higher than 150 mg are not recomm. due to the potent. for QT prolong.
C/I: Hypersens.
Drugs used in Hereditary Angioedema. Conestat Alfa 2100 U/25ml. VIAL: 1x 25ml. Adults up to 84 kg body
weight: One IV inj. of 50 U/kg bdy wt.
Adults of 84 kg bdy wt or greater: One
IV inj. of 4200 U (2 vials).
For tmt. of acute angioedema attacks in
adults with hereditary angioedema (HAE)
due to C1 esterase inhibitor deficiency.
C/I: Hypersens., known or susp. allergy
to rabbits.
Monoclonal Antibody. Lanadelumab 300mg/2ml. VIAL (sol. for inj.): 1×2ml. Each vial is intended for single use only.
The recom. init. dose is 300 mg lanadelumab every 2 wks. by SC admin. only. In pts. who are stably attack free on tmt., a dose reduct. of 300 mg lanadelumab every 4 wks. may be considered, especially in pts. with low wt.
The drug is not intended for tmt. of acute HAE attacks. If a dose is missed, the patient should be instructed to administer the dose as soon as possible ensuring at least 10 d. betwn. doses. No dose adjust. is required in pts. above 65 yrs. of age, or patients with renal or hepatic impair. The inject. should be restricted to the recom. inj. sites: the abdomen, the thighs, and the upper outer arms. Rotation of the inj. site is recom. This drug may be self-admin. or admin. by a caregiver only after pt. training on SC inj. See lit.
Routine prevent. of recurrent attacks of hereditary angioedema (HAE) in pts. aged 12 yrs. and older.
C/I: Hypersens.
